Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2016

Open Access 01-12-2016 | Research Article

Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features

Authors: Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita

Published in: BMC Women's Health | Issue 1/2016

Login to get access

Abstract

Background

Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco.

Methods

We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015. Clinicopathologic and prognostic features have been analyzed. Disease-Free Survival (DFS) and Overall Survival (OS) have been estimated.

Results

Of all cases, forty-nine (17.6 %) were identified as having triple negative breast cancer with a median age of 46 years. The average tumor size was 3.6 cm. The majority of patients have had invasive ductal carcinoma (91.8 %) and 40.4 % of them were grade III SBR. Nodal metastasis was detected in 38.9 % of the patients and vascular invasion was found in 36.6 % of them. About half of the patients had an early disease (53.1 %) and 46.9 % were diagnosed at an advanced stage. Patients with operable tumors (61.2 %) underwent primary surgery and adjuvant chemotherapy. Patients with no operable tumors (26.5 %) received neoadjuvant chemotherapy followed by surgery, and patients with metastatic disease (12.2 %) were treated by palliative chemotherapy. DFS and OS at 5 years were respectively 83.7 and 71.4 %. Among 49, twelve had recurrences, found either when diagnosing them or after a follow-up. Local relapse was 6.1 %. Lung and liver metastases accounted consecutively for 8.2 and 10.2 %. Bone metastases were found in 4.1 % and brain metastases in 2.1 % of the cases.

Conclusion

Our results are in accordance with literature data, particularly what concerning young age and poor prognosis among TNBC phenotype. Therefore, the identification of BRCA mutations in our population seems to be essential in order to better adapt management options for this aggressive form of breast cancer.
Literature
1.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747–52.CrossRefPubMed
2.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. Jama. 2006; 295(21):2492–502.CrossRefPubMed
3.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15):4429–34.CrossRefPubMed
4.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938–48.CrossRefPubMed
5.
Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, et al. Estrogen receptor status in brca1-and brca2-related breast cancer the influence of age, grade, and histological type. Clin Cancer Res. 2004; 10(6):2029–34.CrossRefPubMed
6.
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Marcom PK, et al. Prevalence of brca mutations among women with triple-negative breast cancer (tnbc) in a genetic counseling cohort. Ann Surg Oncol. 2013; 20(10):3254–58.CrossRefPubMed
7.
Young S, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, DeSai D, et al. The prevalence of brca1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009; 9(1):1.CrossRef
8.
Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E. Prognostic role of brca1 mutation in patients with triple-negative breast cancer. Oncol Lett. 2014; 7(1):278–84.PubMed
9.
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009; 115(2):423–8.CrossRefPubMed
10.
Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20):3271–77.CrossRefPubMed
11.
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer. 2012; 118(22):5463–72.CrossRefPubMedPubMedCentral
12.
Beca F, Santos R, Vieira D, Zeferino L, Dufloth R, Schmitt F. Primary relapse site pattern in women with triple-negative breast cancer. Pathol-Res Pract. 2014; 210(9):571–5.CrossRefPubMed
13.
Alberti C, Timsit J, Chevret S. Survival analysis: how to manage censored data? the kaplan-meier’s méthod. Rev Mal Respir. 2005; 22(2 Pt 1):333.CrossRefPubMed
14.
Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA, Amarti A, Mesbahi OE. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of hassan ii university hospital in fez). BMC Res Notes. 2011; 4(1):1.CrossRef
15.
Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H, et al. Triple negative breast cancer in moroccan women: clinicopathological and therapeutic study at the national institute of oncology. BMC Women’s Health. 2012; 12(1):35.CrossRefPubMedPubMedCentral
16.
Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL, Pensa MA, Gonsalves L, Stevens RG, Runowicz CD. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study. Clin Breast Cancer. 2011; 11(5):332–41.CrossRefPubMedPubMedCentral
17.
Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in african american women with triple negative breast cancer: a comparison of epidemiological and molecular factors between african american and caucasian women with triple negative breast cancer. BMC Cancer. 2014; 14(1):1.CrossRef
18.
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, et al. Incidence and outcome of brca mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17(5):1082–9.CrossRefPubMedPubMedCentral
19.
Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, Rudnicka H, Lubinski J, Scott RJ. Prevalence of brca1 and brca2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015; 150(1):71–80.CrossRefPubMed
20.
Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, et al. Brca1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol. 2015; 9(8):1528–38.CrossRefPubMed
21.
Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015; 33(4):304–11.CrossRefPubMed
22.
Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L. [identification of basal-like carcinomas in clinical practice:“ triple zero/brca1-like” carcinomas]. Bull Cancer. 2010; 97(3):357–63.PubMed
23.
Yamashita N, Tokunaga E, Kitao H, Hitchins M, Inoue Y, Tanaka K, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, et al. Epigenetic inactivation of brca1 through promoter hypermethylation and its clinical importance in triple-negative breast cancer. Clin Breast Cancer. 2015; 15(6):498–504.CrossRefPubMed
24.
Kawachi A, Okochi-Takada E, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Ushijima T, et al. 98pbrca1 methylation in triple-negative breast cancer. Ann Oncol. 2015; 26(suppl 9):28–9.CrossRef
25.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the dna repair defect in brca mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917–21.CrossRefPubMed
26.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, et al. Inhibition of poly (adp-ribose) polymerase in tumors from brca mutation carriers. N Engl J Med. 2009; 361(2):123–34.CrossRefPubMed
27.
Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J, Friedlander M, Carmichael J. Phase ii trial of the oral parp inhibitor olaparib in brca-deficient advanced breast cancer. In: ASCO Annual Meeting Proceedings: 2009. p. 501.
28.
Yerushalmi R, Hayes M, Gelmon K. Breast carcinoma–rare types: review of the literature. Ann Oncol.2009;245.
29.
Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, et al. Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast. 2013; 22(5):761–6.CrossRefPubMed
30.
Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in brca1-related breast carcinoma. Cancer. 2003; 98(8):1569–77.CrossRefPubMed
31.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329–34.CrossRefPubMed
32.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275–81.CrossRefPubMed
33.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Abstract s1-11: Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (ctneobc). Cancer Res. 2012; 72(24 Supplement):1–11.
34.
Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol. 2014; 12(1):1.CrossRef
35.
Solin LJ, Hwang WT, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer. 2009; 9(2):96–100.CrossRefPubMed
36.
Freedman GM, Anderson PR, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009; 115(5):946–51.CrossRefPubMedPubMedCentral
37.
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Raad RFA, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and her-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26(14):2373–8.CrossRefPubMed
38.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van De Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001; 98(19):10869–74.CrossRefPubMedPubMedCentral
39.
Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16(Supplement 1):1–11.CrossRefPubMed
Metadata
Title
Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features
Authors
Touria Derkaoui
Joaira Bakkach
Mohamed Mansouri
Ali Loudiyi
Mohamed Fihri
Fatima Zahra Alaoui
Amina Barakat
Bouchra El Yemlahi
Hassan Bihri
Naima Ghailani Nourouti
Mohcine Bennani Mechita
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2016
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-016-0346-y

Other articles of this Issue 1/2016

BMC Women's Health 1/2016 Go to the issue

Research article

Effect of Women’s autonomy on maternal health service utilization in Nepal: a cross sectional study

Research article

Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study

Research article

The association between subjective assessment of menstrual bleeding and measures of iron deficiency anemia in premenopausal African-American women: a cross-sectional study

Research article

A scoping review on determinants of unmet need for family planning among women of reproductive age in low and middle income countries

Research article

Knowledge of obstetric danger signs and associated factors among pregnant women in Erer district, Somali region, Ethiopia

Research article

Gender at the intersection with race and class in the schooling and wellbeing of immigrant-origin students